NCT04955678 - A Comparative Study of ZG-801 and Placebo in Patients With Hyperkalemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 3, 2021

Primary Completion Date

December 26, 2022

Study Completion Date

March 13, 2023

Conditions

Hyperkalemia

Interventions

DRUG

Calcium, hydrolysed divinylbenzene-Me 2-fluoro-2-propenoate-1, 7-octadiene polymer sorbitol complexes

ZG-801 is powder for suspension. In Run-in period, ZG-801 is taken once a day for 4 or 5 weeks. In Double-blind period, ZG-801 is taken once a day for 4 weeks.

DRUG

Placebo

Placebo is powder for suspension. In Double-blind period, Placebo is taken once a day for 4 weeks.

Trial Locations (1)

Unknown

Zeria Investigative Site, Hitachi-Naka